All In Biotech

Drug Trial Radar · NCT06706076

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

A Phase 1/2 Open-Label, Multicenter, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Adult Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (SOLARA)

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

675

Planned (sponsor's estimate)

Start

Jan 9, 2025

Primary completion

Jan 31, 2029

Study completion Jul 31, 2029

Sponsor

Lead sponsor
BlossomHill TherapeuticsIndustry
Sponsor type
Industry
First posted
Nov 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase1/2, open label, multicenter study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics and preliminary anti-tumor activity of BH-30643 in patients with NSCLC having EGFR and/or HER2 mutations. Phase 1 will determine the recommended Phase 2 dose (RP2D) and, if applicable, the maximum tolerated dose (MTD) of BH-30643, both as a monotherapy and in combination with chemotherapy. Phase 2 will further evaluate the antitumor efficacy and safety in specified cohorts determined by EGFR/HER2 mutation subtypes and/or treatment history at the RP2D, as well as the population PK.

Conditions

  • NSCLC (Advanced Non-small Cell Lung Cancer)

Interventions

  • BH-30643Drug

    BH-30643 will be provided as either 10 mg or 40 mg capsules or tablets. Subjects will take BH-30643 orally depending on their dose level assignment.

  • BH-30643 combo therapy with Carboplatin/PemetrexedDrug

    BH-30643 will be provided as either 10 mg or 40 mg capsules or tablets in combo therapy with Carboplatin/Pemetrexed. Subjects will take BH-30643 orally depending on their dose level assignment. Carboplatin/Pemetrexed will be administered according to standard of care

  • BH-30643Drug

    BH-30643 will be provided as either 10 mg or 40 mg capsules. Subjects will take BH-30643 orally depending on their dose level assignment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicities (DLTs) (Phase 1, Dose Escalation)Time frame: Within the first 21 days of the first dose of BH-30643.
  2. Recommended Phase 2 dose (RP2D) (Phase 1, Dose Expansion/Optimization)Time frame: Within 21 days of last participant dosed during Dose Expansion/Optimization.
  3. Objective Response Rate (ORR) (Phase 2)Time frame: Approximately 3 years after the first participant dosed.

Locations

43 sites in 9 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Hospital - Arizona

    Phoenix, Arizona · Recruiting

  • The Regents of the University of California - Irvine, CA Campus

    Irvine, California · Recruiting

  • UC San Diego Moores Cancer Center

    La Jolla, California · Recruiting

  • Cedars-Sinai Cancer at Cedars Sinai Medical Center

    Los Angeles, California · Recruiting

  • University of California, Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • Stanford University Medical Center

    Stanford, California · Recruiting

  • Yale University - Cancer Center

    New Haven, Connecticut · Recruiting

  • Georgetown University Medical Center

    Washington D.C., District of Columbia · Recruiting

  • Mayo Clinic - Florida

    Jacksonville, Florida · Recruiting

  • Sarah Cancer Research Institution - Florida Cancer Specialist

    Orlando, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion

    Chicago, Illinois · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Henry Ford Health

    Detroit, Michigan · Recruiting

  • Mayo Clinic Hospital - Rochester, MN

    Rochester, Minnesota · Recruiting

  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Duke Cancer Institute

    Durham, North Carolina · Recruiting

  • Thomas Jefferson University, Sidney Kimmel Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • Sarah Cannon Research Institute, LLC

    Nashville, Tennessee · Recruiting

  • The University of Texas - M.D. Anderson Cancer Center

    Houston, Texas · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

  • Austin Health

    Heidelberg, Victoria, Australia · Recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia · Recruiting

  • Cross Cancer Institute

    Edmonton, Alberta, Canada · Recruiting

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

  • Queen Mary Hospital

    Hong Kong, Hong Kong · Recruiting

  • Prince of Wales Hospital

    Shatin, New Territories, Hong Kong · Recruiting

  • National Cancer Center Hospital East

    Kashiwa, Chiba, Japan · Recruiting

  • Kindai University Hospital

    Osakasayama-shi, Osaka, Japan · Recruiting

  • National Cancer Center Hospital

    Tsukiji, Tokyo, Japan · Recruiting

  • Sarawak General Hospital

    Kuching, Sarawak, Malaysia · Recruiting

  • National University Hospital

    Kent Ridge, Singapore · Recruiting

  • National Cancer Centre - Singapore

    Singapore, Singapore · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Asan Medical Center

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.